Share Name Share Symbol Market Type Share ISIN Share Description
Hikma Pharmaceuticals LSE:HIK London Ordinary Share GB00B0LCW083 ORD SHS 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +5.00p +0.31% 1,601.00p 1,600.00p 1,602.00p 1,621.00p 1,592.00p 1,592.00p 52,363 09:33:08
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1,579.1 170.1 53.9 30.5 3,851.13

Hikma Pharmaceuticals (HIK) Latest News

More Hikma Pharmaceuticals News
Hikma Pharmaceuticals Takeover Rumours

Hikma Pharmaceuticals (HIK) Share Charts

1 Year Hikma Pharmaceuticals Chart

1 Year Hikma Pharmaceuticals Chart

1 Month Hikma Pharmaceuticals Chart

1 Month Hikma Pharmaceuticals Chart

Intraday Hikma Pharmaceuticals Chart

Intraday Hikma Pharmaceuticals Chart

Hikma Pharmaceuticals (HIK) Discussions and Chat

Hikma Pharmaceuticals Forums and Chat

Date Time Title Posts
22/6/201708:17Hikma Pharmaceuticals531
13/1/201515:12 *** Hikma ***98

Add a New Thread

Hikma Pharmaceuticals (HIK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
08:33:081,601.0057912.57AT
08:33:081,601.001352,161.35AT
08:33:081,601.001602,561.60AT
08:33:081,601.00991,584.99AT
08:33:071,601.003064,899.06AT
View all Hikma Pharmaceuticals trades in real-time

Hikma Pharmaceuticals (HIK) Top Chat Posts

DateSubject
23/6/2017
09:20
Hikma Pharmaceuticals Daily Update: Hikma Pharmaceuticals is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HIK. The last closing price for Hikma Pharmaceuticals was 1,596p.
Hikma Pharmaceuticals has a 4 week average price of 1,583p and a 12 week average price of 1,573p.
The 1 year high share price is 2,703p while the 1 year low share price is currently 1,573p.
There are currently 240,545,322 shares in issue and the average daily traded volume is 1,303,131 shares. The market capitalisation of Hikma Pharmaceuticals is £3,889,617,856.74.
21/5/2017
18:39
fez77: Interactive Investor:- Still, analysts remain undeterred. Stifel's Max Herrmann reckons the stock can recapture August highs at the £23 level, with his unchanged target price now suggesting potential upside of 43%. This despite "ongoing difficulties" in delivering the potential of its February 2016 acquisition of Roxane Laboratories. Herrmann reckons the lowering of its Generics forecasts will slash 4% off Hikma's earnings per share. However, he remains "confident of Hikma's long-term potential, with generic Advair, first to file Zytiga and first to file Xyrem opportunities still to come". A forecast 2017 price/earnings (PE) ratio of 19.6 times represents an 18% discount to its UK specialty peers and means the firm's potential is not currently reflected in the share price, Herrmann added.
19/5/2017
14:23
bantam175: This is nuts. They've dropped their revenue forecast by $130million which has brought the share price down from £22 to here £16.5 Reducing the company value by 239970000 (shares in issue)* 5.5 (£'s drop in price) = £1,319,835,000. They must be a bargain at this price surely? Drop over last couple of months seems completely out of all proportion to me. imho dyor etc.
10/4/2017
18:57
vatattack: Hikma Pharmaceuticals got a boost on Monday as Numis upgraded the stock to 'buy' from 'add'.It said that following Mylan's Complete Response Letter, the market is now overly discounting Hikma's prospects for gaining approval of its generic version of GlaxoSmithKline's bestselling asthma drug Advair this year.In addition, the share price is now also heavily discounting the core business, Numis said."If Hikma gains FDA approval this year, most likely with minor deficiencies in a complete response letter, we see potential for a slight upgrade to our low-end FY17 forecasts, and a material upgrade to our low-end FY18 forecasts (potentially more than 10%), and envisage a higher multiple being warranted post upgrades (14x FY18 EV/EBITDA well underpinned versus peers)."Numis reckons Hikma has a stronger chance of approval than Mylan because it included 12-18 year olds in its study and has benefited from the expertise of Vectura, a business that, unlike Mylan, has a generic version of Advair Diskus approved in Europe in partnership with Sandoz."In our opinion the current share price is well underpinned by the core business (more than 25% upside), with a free option on generic Advair. This is an asymmetric risk worth taking, with the catalyst now a month away and potential for more than 50% returns if Hikma's generic Advair is approved first time, or with minor deficiencies."In its final results on 15 March, Hikma said it expected revenue for the Generics business to be around $800m this year, with an improvement in the mix of sales and new product launches more than offsetting the impact of increased competition on the marketed portfolio and a reduction in contract manufacturing revenue.The group said certain new launches were expected to contribute around 15% of Generics revenue in 2017, primarily generic Advair, which was assumed to be launched in the second half of the year.Numis has a 2,350p price target on Hikma.
15/3/2017
09:54
broadwood: Hikma Pharmaceuticals Plc using EPIC/TICKER code LON:HIK has had its stock rating noted as ‘Reiterates217; with the recommendation being set at ‘BUY’ this morning by analysts at Cantor Fitzgerald. Hikma Pharmaceuticals Plc are listed in the Health Care sector within UK Main Market. Cantor Fitzgerald have set a target price of 2500 GBX on its stock. This now indicates the analyst believes there is a possible upside of 14.7% from the opening price of 2180 GBX. Over the last 30 and 90 trading days the company share price has increased 205 points and increased 450 points respectively
28/1/2017
11:14
fez77: No idea when next trading statement will be but full years figures should be available in March. Darhold appears to be a vehicle for Directors etc to hold shares in Hikma. An old Guardian article (May 2015)at https://www.theguardian.com/business/marketforceslive/2015/may/11/hikma-higher-on-buy-note-and-acquisition-prospects included the quote:- "The Jordanian-based company has expanded rapidly over the past few years by building a world-class injectable generics business and enjoyed strong growth as a branded pharma player in its home MENA markets. Following the recent decline in Hikma’s share price, the company now trades at a 10% 2015 PER discount to its peers. We believe the sell-off is overdone, and we are therefore upgrading our recommendation to Buy. Any reticence to consider Hikma seems to primarily be concerned with Hikma’s roots as a Jordanian, family-run company with a large operation in the Middle East. However, with the family controlling 28.8% of the company through their Darhold Ltd stake, management interests are well aligned with the shareholders. We believe large acquisitions are possible in the near future and will remain an integral part of Hikma’s business plan...." As I said before, it is a bumpy ride, but one where the largest shareholders are prepared to put their money where their mouth is!
19/12/2016
12:00
broadwood: Quite why the share price fell so much was very surprising to me. Probably over the worst and strength returning.
04/11/2016
15:44
broadwood: Numis has upgraded its recommendation on Hikma Pharmaceuticals [LON:HIK] to 'buy' from 'hold' ahead next week's third quarter update and following a 35 per cent decline in the share price over the past three months. The broker pointed out that the shares have significantly underperformed the UK Mid-Cap Healthcare and Global Specialty Pharma sectors but sees the Q3 results on 10th November and the "Meet the Management" event on 15th November as the catalysts for a re-rating. Analyst have set a new target price of 2,350 pence per share
01/9/2016
13:58
sandeep67: 3 directors spent millions on shares each yesterday. Looks like Institutions want in by dropping the price to encourage scared selling. Can't see why the share price is inversing against the huge guys
06/6/2016
15:18
broadwood: Jordanian drugs-maker Hikma became the fourth pharma constituent of the FTSE 100 in March 2015, before falling out of favour with investors and dropping out of the top index a year later. But a recent positive trading statement has seen the share price rally enormously and last month the group rejoined the FTSE 100 having replaced satellite firm Insmarsat.
29/7/2015
13:17
broadwood: Jefferies ups Hikma to 'buy', says Roxane deal is a 'game changer' (ShareCast News) - Hikma Pharmaceuticals got a boost after Jefferies upgraded the stock to 'buy' from 'hold' and raised its price target to 2,615p from 2,134p as it integrates the company's "transformational" deal with Roxane Laboratories. "In our view Hikma is transitioning to a period of remarkable growth as it executes on recent acquisitions and we expect share price momentum to continue despite the 12% rally," it said, adding that Hikma is now its preferred name in the EMEA generics sector. Jefferies said the acquisition of Roxane, at $2.65bn, is a game-changer for Hikma in the US and provides a platform and pipeline to grow its business with opportunities to create further value from potential synergies and diversify its revenue base. It noted that Roxane has 88 differentiated products across specialised segments which are highly complementary to Hikma's existing US business. The combination will create the number 6 player in the US generics market, from 20 previously, said Jefferies. It raised its 2016 earnings per share estimate by 4% and 2017 by 14%, saying it believes the integration of Roxane combined with solid market fundamentals should improve Hikma's earnings power despite higher interest charges and equity dilution to shareholders.
Hikma Pharmaceuticals share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20170623 08:52:31